Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

480 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models.
Agulló-Ortuño MT, Mancebo E, Grau M, Núñez Sobrino JA, Paz-Ares L, López-Martín JA, Flández M. Agulló-Ortuño MT, et al. Int J Mol Sci. 2023 Aug 21;24(16):13005. doi: 10.3390/ijms241613005. Int J Mol Sci. 2023. PMID: 37629186 Free PMC article.
Signature-driven repurposing of Midostaurin for combination with MEK1/2 and KRASG12C inhibitors in lung cancer.
Macaya I, Roman M, Welch C, Entrialgo-Cadierno R, Salmon M, Santos A, Feliu I, Kovalski J, Lopez I, Rodriguez-Remirez M, Palomino-Echeverria S, Lonfgren SM, Ferrero M, Calabuig S, Ludwig IA, Lara-Astiaso D, Jantus-Lewintre E, Guruceaga E, Narayanan S, Ponz-Sarvise M, Pineda-Lucena A, Lecanda F, Ruggero D, Khatri P, Santamaria E, Fernandez-Irigoyen J, Ferrer I, Paz-Ares L, Drosten M, Barbacid M, Gil-Bazo I, Vicent S. Macaya I, et al. Nat Commun. 2023 Oct 10;14(1):6332. doi: 10.1038/s41467-023-41828-z. Nat Commun. 2023. PMID: 37816716 Free PMC article.
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.
Desai J, Alonso G, Kim SH, Cervantes A, Karasic T, Medina L, Shacham-Shmueli E, Cosman R, Falcon A, Gort E, Guren T, Massarelli E, Miller WH Jr, Paz-Ares L, Prenen H, Amatu A, Cremolini C, Kim TW, Moreno V, Ou SI, Passardi A, Sacher A, Santoro A, Stec R, Ulahannan S, Arbour K, Lorusso P, Luo J, Patel MR, Choi Y, Shi Z, Mandlekar S, Lin MT, Royer-Joo S, Chang J, Jun T, Dharia NV, Schutzman JL; GO42144 Investigator and Study Group; Han SW. Desai J, et al. Nat Med. 2024 Jan;30(1):271-278. doi: 10.1038/s41591-023-02696-8. Epub 2023 Dec 5. Nat Med. 2024. PMID: 38052910 Free PMC article. Clinical Trial.
Actionable non-small cell lung cancer mutation identification by comprehensive genomic profiling for clinical trial enrollment: the European Program for the ROutine testing of Patients with Advanced lung cancer (EPROPA).
Passiglia F, Listì A, Bironzo P, Merlini A, Benso F, Napoli F, Barbu FA, Zambelli V, Tabbò F, Reale ML, Sini C, Roca E, Taveggia PA, Simionato F, Buffoni L, Mazilu L, Barbieri V, Pignataro D, Araujo A, Paz-Ares L, Felip E, Secen N, Comanescu A, Ramizi KM, Bettini AC, Scotti V, Linardou H, Mohorcic K, Meoni G, Giannarelli D, Volante M, Malapelle U, Vallone S, Scagliotti G, Righi L, Novello S. Passiglia F, et al. Among authors: paz ares l. J Thorac Oncol. 2024 Dec 16:S1556-0864(24)02529-2. doi: 10.1016/j.jtho.2024.12.010. Online ahead of print. J Thorac Oncol. 2024. PMID: 39694416 Free article.
Lurbinectedin is an effective alternative to platinum rechallenge and may restore platinum sensitivity in patients with sensitive relapsed small cell lung cancer.
Dómine Gómez M, Subbiah V, Peters S, Sala MA, Trigo J, Paz-Ares L, Nieto Archilla A, Gomez Garcia J, Alvarez García C, López-Vilariño de Ramos JA, Kahatt Lopez C, Fernandez CM. Dómine Gómez M, et al. Among authors: paz ares l. Expert Rev Anticancer Ther. 2024 Dec 12:1-15. doi: 10.1080/14737140.2024.2438067. Online ahead of print. Expert Rev Anticancer Ther. 2024. PMID: 39660812 Review.
RELAY: Final Overall Survival for Erlotinib Plus Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC.
Nakagawa K, Garon EB, Seto T, Nishio M, Aix SP, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Nishino K, Yoh K, Shih JY, Chik JYK, Moro-Sibilot D, Puri T, Chacko Varughese S, Frimodt-Moller B, Visseren-Grul C, Reck M. Nakagawa K, et al. Among authors: paz ares l. J Thorac Oncol. 2024 Nov 30:S1556-0864(24)02495-X. doi: 10.1016/j.jtho.2024.11.032. Online ahead of print. J Thorac Oncol. 2024. PMID: 39622410 Free article.
Plain language summary: tarlatamab for patients with previously treated small cell lung cancer.
Ahn MJ, Cho BC, Felip E, Korantzis I, Ohashi K, Majem M, Juan-Vidal O, Handzhiev S, Izumi H, Lee JS, Dziadziuszko R, Wolf J, Blackhall F, Reck M, Alvarez JB, Hummel HD, Dingemans AC, Sands J, Akamatsu H, Owonikoko TK, Ramalingam SS, Borghaei H, Johnson ML, Huang S, Mukherjee S, Minocha M, Jiang T, Martinez P, Anderson ES, Paz-Ares L. Ahn MJ, et al. Among authors: paz ares l. Future Oncol. 2024 Nov 12:1-10. doi: 10.1080/14796694.2024.2402152. Online ahead of print. Future Oncol. 2024. PMID: 39530627
Lung cancer research and treatment: global perspectives and strategic calls to action.
Meyer ML, Peters S, Mok TS, Lam S, Yang PC, Aggarwal C, Brahmer J, Dziadziuszko R, Felip E, Ferris A, Forde PM, Gray J, Gros L, Halmos B, Herbst R, Jänne PA, Johnson BE, Kelly K, Leighl NB, Liu S, Lowy I, Marron TU, Paz-Ares L, Rizvi N, Rudin CM, Shum E, Stahel R, Trunova N, Bunn PA, Hirsch FR. Meyer ML, et al. Among authors: paz ares l. Ann Oncol. 2024 Dec;35(12):1088-1104. doi: 10.1016/j.annonc.2024.10.006. Epub 2024 Oct 15. Ann Oncol. 2024. PMID: 39413875 Review.
480 results